Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to  ROR1 is a common target in medicine.

ROR 1, one member of the receptor tyrosine kinase-like orphan receptor (ROR) family, belongs to the type I receptor tyrosine kinase (receptor tyrosine kinase, RTK) family. Unlike the ROR family in nuclear receptors, ROR is a class of membrane receptors. ROR 1 is a transmembrane receptor that contains extracellular parts, transmembrane regions, and intracellular regions. The extracellular part includes the immunoglobulin-like domain (IG), cysteine-rich domain (CRD), and Kringle domain (KD). The intracellular part includes a tyrosine kinase domain, two serine / threonine-rich domains (S / T), and a proline-rich domain (PRD). The proline-rich domain of ROR 1 physically interacts with cohesion proteins by recruiting SH3 domain-containing proteins, including HS1, DOCK 2, and cortactin, responsible for activating cell migration and proliferation signals, causing resistance to apoptosis.

ROR 1 can play important roles in a variety of physiological processes by mediating signaling in the non-classical Wnt signaling pathway (non-canonical Wnt pathways), including the regulation of cell division, proliferation, migration, and cell chemotaxis, especially Wnt 5 a. WNT / ROR 1 signaling is induced by binding to a non-canonical WNT ligand that triggers the formation of a complex between ROR 1 and a FZD receptor, respectively. Signal transduction is the phosphorylation of ROR 1 by several kinases, leading to the inhibition of antiapoptotic pathways on one hand and the activation of downstream pathways such as WNT / PCP, MAPK / ERK, PI3K / AKT) or NF- κ B on the other. These either trigger cytoskeletal rearrangements associated with enhanced tumor cell migration or induce a transcriptional response leading to the expression of genes that promote cell proliferation, survival, EMT, or treatment resistance. 

Currently, various immune drugs targeting ROR1 targets are in the updating iteration, and taking the disease alone or in combination with other products has become a new approach with remarkable achievements. The ROR1 targets have shown important research value and application prospects in both biology and drug research and development. With further research and detection technology advances, ROR1 target products are also essential in medical research. Alpha Lifetech can provide ROR1 with corresponding products and help each customer's research and development. Alpha Lifetech focuses on high-precision detection development and validation services to support drug screening and biosimilar discovery. Our detection methods, including ELISA, cell-based functional testing, and flow cytometry, have undergone rigorous sensitivity, specificity, and reproducibility testing. In addition to testing and development, our team also provides data analysis, scheme optimization, and cross-species reactivity testing to ensure reliable results.